Myeloproliferative Neoplasm, BCR-ABL1 Negative

Myeloproliferative Neoplasm, BCR-ABL1 Negative — Trials · CancerIndex

Clinical trials

Registered studies

333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 94
Recruiting: 50
Ph III recruiting: 7
Growth YoY: —
Industry share: 41%
Top sponsor: City of Hope Medical Center
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04655118	Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis	unknown	Phase 2	121	Telios Pharma, Inc.INDUSTRY	13	May 10, 2024	clinicaltrials
NCT01298934	LBH589 (Panobinostat) for the Treatment of Myelofibrosis	unknown	Phase 1 / Phase 2	22	Ronald HoffmanOTHER	1	Mar 6, 2015	clinicaltrials
NCT00668421